Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 08 April, 2004

XTL Biopharm Ltd

HCV hMAb Patent Granted

XTL Biopharmaceuticals Ltd
08 April 2004

XTLbio Announces Grant of HCV Human Monoclonal Antibody Patent

Patent Covering Antibodies Directed Against Hepatitis C Virus Recently Licensed
from Stanford University

Rehovot, Israel, 8 April 2004 - XTL Biopharmaceuticals Ltd. (XTLbio) announces
the issuance of US Patent No. 6,692,908 (the '908 Patent') entitled, 'Prevention
and treatment of HCV infection employing antibodies that inhibit the interaction
of HCV virions with their receptor'. The patent covers human monoclonal
antibodies (MAbs) directed against the envelope glycoprotein 2 (E2) of the
hepatitis C virus (HCV). The patent was recently licensed from Stanford
University. The MAbs disclosed in the patent include a potent neutralizing
antibody that could potentially enhance XTLbio's treatment candidate, HepeX-C,
and a human monoclonal antibody based product, currently in phase 2 clinical
studies in liver transplant patients. HepeX-C has shown anti-viral activity in
phase 1 studies in chronic HCV patients. In line with XTLbio's previously
announced strategy in HCV liver transplantation, XTLbio intends to submit an IND
for a combination of HepeX-C with one of the newly licensed antibodies later
this year. The addition of a second antibody could increase the potency of the
product by minimizing emergence of viral escape mutants and/or enhancing
anti-viral activity.

'The grant of the '908 Patent' strengthens our intellectual property presence in
the area of human monoclonal antibody therapeutics directed against hepatitis
C,' stated Mirit Lotan, PhD, Senior Director of Patents and Technology
Assessment for XTLbio. 'The '908 Patent' is XTLbio's first issued patent in the
area of HCV antibodies and will provide a strong intellectual property base for
the company's enhanced HepeX-C product in the US'.

The human monoclonal anti HCV antibodies covered by the 908 patent, bind to E2
epitopes common to multiple HCV genotypes. The antibodies were developed in the
laboratory of Dr Steven Foung at Stanford University, and were extensively
evaluated by XTLbio using the Company's proprietary HCV in vitro and in vivo
validation systems to assess anti-viral activity.


Dr. Martin Becker, President and CEO, Tel: +972-8-930-4440

Financial Dynamics
David Yates, Tel: +44 (0) 20 7831 3113

Notes to Editors

About XTLbio
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeX(TM) product line - now in clinical
trials - has the potential to introduce revolutionary therapies for viral
hepatitis, including prevention of re-infection in transplanted livers, the
Company's primary focus, and a longer-term cocktail approach in treating chronic
illness. XTLbio believes its primary competitive advantage lies in its patented
Trimera(TM) technology, which enables the development of fully human monoclonal
antibodies and models of human disease for pre-clinical drug validation.
Established in 1993, XTLbio became a public company in 2000 and its shares are
listed on the Official List of the UK Listing Authority and are traded on the
London Stock Exchange under the symbol XTL.

About hepatitis C
Hepatitis C is a major public health concern. The World Health Organization
estimates that 170 million people worldwide are chronic carriers of the
hepatitis C virus (HCV) and that 3 to 4 million people are newly infected each
year. It is expected that 25 to 35% of these chronic patients will develop
progressive liver disease including cirrhosis and liver cancer. Hepatitis C is
the single leading cause of liver transplantation. The US Centres for Disease
Control and Prevention estimate that approximately 4 million people in the
United States (almost 2% of the population) have been infected with HCV, of
whom, approximately 3 million are chronically ill. Hepatitis C is the cause of
an estimated 8,000 to 10,000 deaths annually in the US.

About HCV-related liver transplant prophylaxis
Approximately 5% of chronic HCV patients will develop end-stage liver disease,
and ultimately may require liver transplantation. Today, there is a major
problem associated with HCV-related liver transplantation. Although the infected
liver - the major source of viral replication - has been removed, free-floating
virus in the patient's serum re-infects the healthy transplanted liver in a
matter of weeks. Disease progression in re-infected patients is several times
faster and, in many cases, a re-transplant becomes necessary. At present, there
is no available solution to this problem.

About the treatment of chronic hepatitis C
The existing first-line chronic HCV therapy is often associated with a 50-60%
success rate but it is limited by severe side effects, including anaemia,
fatigue, hair loss and depression. Due to the relatively limited efficacy and
toxicity of this treatment, chronic HCV is still considered to be an unmet
medical need, with estimated worldwide annual sales for all products treating
chronic hepatitis C reaching US$4 billion in 2004.

HepeX(TM), Trimera(TM), XTL(TM) and XTLbio(TM) are trademarks of XTL 
Biopharmaceuticals Ltd.

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t